In a large population of people with diabetes, the use of GLP-1 receptor agonists was not linked to an increased risk for ...

The weight-loss succession race is heating up. Here's how biopharma execs talked up those efforts at JPM this week.

Patients with overweight or obesity who used maridebart cafraglutide experienced significant weight loss at 1 year, according ...

As the Biden presidency winds down, the administration touted its Cancer Moonshot accomplishments, including regulatory action against forever chemicals and ethylene oxide, expanded access to cancer ...

BioWorld™ published by Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, has released its highly anticipated 2024 Year in Review series. This multipart special ...

Dr Daniel Rosen, who is a surgeon and obesity medicine specialist based out of New York, says a 'legitimate number' of his ...

A study by Mass General Brigham investigators shows persistent racial disparities and growing sex disparities between ...

Novo Nordisk and Valo Health have expanded their agreement to discover and develop new treatments for type 2 diabetes, ...

A study found that disruptions in homeostasis from quick weight reduction by consuming GLP-1 drug can elevate cortisol - a ...

Series Recaps Biopharma, MedTech, and Science Trends and Breakthroughs That Shaped the Year LONDON, Jan. 16, 2025 /PRNewswire/ -- BioWorld published by Clarivate Plc (NYSE:CLVT), a leading ...

I'm cautious about Novo Nordisk's short-term prospects due to the recent selloff, but see long-term potential with high ...

The following is a summary of “Association between incretin-based drugs and risk of cholangiocarcinoma among patients with ...